多能干细胞治疗视网膜退行性疾病:从实验室到临床转化的现状与挑战
Pluripotent stem cells in the treatment of retinal degenerative diseases:Current situation and challenges from bench to bedside
郭艳 1鲍莉 1纪猛 2吴月红1
作者信息
- 1. 浙江理工大学生命科学与医药学院,杭州 310018
- 2. 浙江泉生生物工程有限公司,杭州 310018
- 折叠
摘要
视网膜色素上皮细胞(Retinal pigment epithelial cells,RPE)是位于视网膜底部致密的细胞层,其损伤导致年龄相关性黄斑变性(Age-related macular degeneration,AMD)、Stargardt 病(Stargardt macular dystrophy,STGD)和色素性视网膜炎(Retinitis pigmentosa,RP)等视网膜疾病,RPE移植已成为治疗RPE损伤性疾病的有效方案.来源于人多能干细胞(Human pluripotent stem cells,hPSC)的视网膜色素上皮细胞,具有与人原代RPE相似的功能和容易制备等优点,已成为RPE移植的最主要细胞来源之一.文章对hPSC-RPE治疗视网膜退行性疾病的临床试验进展进行了总结和归纳,并阐述了目前面临的挑战与风险.
Abstract
Retinal pigment epithelial(RPE)cells are located in a dense layer of cells at the bottom of the retina,and their damage can result in age-related macular degeneration(AMD),Stargardt macular dystrophy(STGD),Retinitis pigmentosa(RP)and other retinal degenerative diseases.RPE transplantation has become an effective treatment for such diseases at present.RPE cells derived from human pluripotent stem cells(hPSC),namely hPSC-RPE,have become the main source of RPE transplantation because of their similar function and easy preparation to human primary RPE.This article summarizes the clinical trials of hPSC-RPE in the treatment of retinal degenerative diseases,and expounds the challenges and risks we are facing at present.
关键词
人多能干细胞/视网膜色素上皮细胞/年龄相关性黄斑变性/Stargardt病/色素性视网膜炎/细胞治疗Key words
human pluripotent stem cells/retinal pigment epithelium/age-related macular degeneration/stargardt macular dystrophy/retinitis pigmentosa/cell therapy引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据